MX370397B - Vacuna para enfermedad intrauterina. - Google Patents
Vacuna para enfermedad intrauterina.Info
- Publication number
- MX370397B MX370397B MX2015006862A MX2015006862A MX370397B MX 370397 B MX370397 B MX 370397B MX 2015006862 A MX2015006862 A MX 2015006862A MX 2015006862 A MX2015006862 A MX 2015006862A MX 370397 B MX370397 B MX 370397B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- pyogenes
- whole cells
- necrophorum
- coli
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/114—Fusobacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/18—Arrangements for indicating condition of container contents, e.g. sterile condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Abstract
La presente invención se refiere a una composición veterinaria para usarse para la profilaxis de metritis puerperal en un rumiante, en donde la composición veterinaria está formulada para ser administrable por vía subcutánea al mamífero rumiante, la composición veterinaria comprende la proteína leucotoxina (LKT) de F. necrophorum, la proteína adhesina fimbrial (FimH) de E.coli tipo 1, y la proteína piolisina de T.pyogenes (PLO).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731333P | 2012-11-29 | 2012-11-29 | |
PCT/US2013/063866 WO2014084964A1 (en) | 2012-11-29 | 2013-10-08 | Vaccine for intrauterine disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015006862A MX2015006862A (es) | 2016-06-29 |
MX370397B true MX370397B (es) | 2019-12-11 |
Family
ID=50828340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006862A MX370397B (es) | 2012-11-29 | 2013-10-08 | Vacuna para enfermedad intrauterina. |
MX2019012044A MX2019012044A (es) | 2012-11-29 | 2015-05-29 | Vacuna para enfermedad intrauterina. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012044A MX2019012044A (es) | 2012-11-29 | 2015-05-29 | Vacuna para enfermedad intrauterina. |
Country Status (12)
Country | Link |
---|---|
US (4) | US9533034B2 (es) |
EP (2) | EP3545970A1 (es) |
JP (1) | JP6301945B2 (es) |
AU (1) | AU2013353403B2 (es) |
BR (3) | BR112015012288B1 (es) |
CA (1) | CA2893072C (es) |
ES (1) | ES2718491T3 (es) |
HU (1) | HUE043129T2 (es) |
MX (2) | MX370397B (es) |
NZ (2) | NZ708669A (es) |
RU (1) | RU2672589C2 (es) |
WO (1) | WO2014084964A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ708669A (en) * | 2012-11-29 | 2019-12-20 | Univ Cornell | Vaccine for intrauterine disease |
MX2017011648A (es) * | 2015-03-12 | 2017-11-02 | Zoetis Services Llc | Metodos de piolisina y composiciones. |
WO2017083367A1 (en) * | 2015-11-09 | 2017-05-18 | Epitopix, Llc | Polypeptides of fusobacterium and methods of use |
KR102474924B1 (ko) | 2020-04-22 | 2022-12-06 | 영남대학교 산학협력단 | 대장균 부착 단백질 FimH를 유효성분으로 포함하는 항암 면역 증강용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69133172T2 (de) * | 1990-06-07 | 2003-04-30 | Bayer Ag | Bacterin zur Behandlung von Lebernekrose verursacht durch F. Necrophorum |
AU675234B2 (en) | 1992-06-26 | 1997-01-30 | Kansas State University Research Foundation | Fusobacterium necrophorum leukotoxoid vaccine |
US5455034A (en) * | 1992-06-26 | 1995-10-03 | Kansas State University Research Foundation | Fusobacterium necrophorum leukotoxoid vaccine |
ATE506074T1 (de) | 1995-06-07 | 2011-05-15 | Univ Kansas State | Actinomyces pyogenes und actinomyces pyogenes/fusobakterium necrophorum impfstoffe zur immunisierung von vieh und schafen |
US6669940B2 (en) * | 2000-04-25 | 2003-12-30 | Kansas University Research Foundation | Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof |
CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
WO2010124085A2 (en) * | 2009-04-23 | 2010-10-28 | Cornell University | Compositions and methods for preventing and treating uterine disease |
NZ708669A (en) * | 2012-11-29 | 2019-12-20 | Univ Cornell | Vaccine for intrauterine disease |
-
2013
- 2013-10-08 NZ NZ708669A patent/NZ708669A/en unknown
- 2013-10-08 RU RU2015125646A patent/RU2672589C2/ru active
- 2013-10-08 MX MX2015006862A patent/MX370397B/es active IP Right Grant
- 2013-10-08 CA CA2893072A patent/CA2893072C/en active Active
- 2013-10-08 NZ NZ754388A patent/NZ754388A/en unknown
- 2013-10-08 US US14/647,623 patent/US9533034B2/en active Active
- 2013-10-08 BR BR112015012288-4A patent/BR112015012288B1/pt active IP Right Grant
- 2013-10-08 HU HUE13858593A patent/HUE043129T2/hu unknown
- 2013-10-08 EP EP19161840.4A patent/EP3545970A1/en active Pending
- 2013-10-08 BR BR122019025365-0A patent/BR122019025365B1/pt active IP Right Grant
- 2013-10-08 WO PCT/US2013/063866 patent/WO2014084964A1/en active Application Filing
- 2013-10-08 EP EP13858593.0A patent/EP2925353B1/en active Active
- 2013-10-08 ES ES13858593T patent/ES2718491T3/es active Active
- 2013-10-08 JP JP2015545043A patent/JP6301945B2/ja active Active
- 2013-10-08 AU AU2013353403A patent/AU2013353403B2/en active Active
- 2013-10-08 BR BR122019025362-5A patent/BR122019025362B1/pt active IP Right Grant
-
2015
- 2015-05-29 MX MX2019012044A patent/MX2019012044A/es unknown
-
2016
- 2016-12-22 US US15/388,334 patent/US9981032B2/en active Active
-
2018
- 2018-04-18 US US15/955,928 patent/US20180236055A1/en not_active Abandoned
-
2019
- 2019-08-09 US US16/537,248 patent/US10821169B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10821169B2 (en) | 2020-11-03 |
HUE043129T2 (hu) | 2019-08-28 |
CA2893072C (en) | 2023-10-03 |
AU2013353403A1 (en) | 2015-07-02 |
ES2718491T3 (es) | 2019-07-02 |
JP2016507479A (ja) | 2016-03-10 |
EP3545970A1 (en) | 2019-10-02 |
RU2672589C2 (ru) | 2018-11-16 |
US20190358311A1 (en) | 2019-11-28 |
US20180236055A1 (en) | 2018-08-23 |
JP6301945B2 (ja) | 2018-03-28 |
EP2925353A4 (en) | 2016-08-10 |
US9533034B2 (en) | 2017-01-03 |
BR122019025362B1 (pt) | 2022-07-26 |
RU2015125646A (ru) | 2017-01-10 |
NZ708669A (en) | 2019-12-20 |
EP2925353A1 (en) | 2015-10-07 |
US20170100473A1 (en) | 2017-04-13 |
MX2019012044A (es) | 2020-01-13 |
WO2014084964A1 (en) | 2014-06-05 |
US9981032B2 (en) | 2018-05-29 |
MX2015006862A (es) | 2016-06-29 |
NZ754388A (en) | 2022-05-27 |
BR112015012288A2 (pt) | 2018-02-06 |
EP2925353B1 (en) | 2019-03-13 |
AU2013353403B2 (en) | 2018-04-19 |
BR122019025365B1 (pt) | 2022-07-26 |
BR112015012288B1 (pt) | 2022-07-26 |
US20150335725A1 (en) | 2015-11-26 |
CA2893072A1 (en) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500284A1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
UA110806C2 (uk) | Мікобактеріальна антигенна композиція | |
MX2019012044A (es) | Vacuna para enfermedad intrauterina. | |
IN2015DN02729A (es) | ||
PH12014501991B1 (en) | Phenicol antibacterials | |
UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
IN2014DN06920A (es) | ||
MX2015015518A (es) | Metodos y composiciones para el tratamiento del cancer. | |
NZ723750A (en) | Compositions and methods for the treatment of her2/neu over-expressing tumors | |
BR112014027087A2 (pt) | tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente | |
BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |